Newly Nasdaq-listed Calliditas surges after lead kidney drug hits primary endpoint
Calliditas still hasn’t proven to patients that their kidney drug has long-term benefits, but the company says they’ve seen more than enough to go to regulators.
The Swedish company, which recently raised a $90 million Nasdaq IPO, announced on Sunday that their lead drug Nefecon had hit primary and secondary endpoints in the first part of a Phase III trial, successfully improving kidney function in patients with an inflammatory kidney disease called primary IgA nephropathy. They will use the data to ask the FDA and EMA for accelerated approval in the first quarter of 2021, part of a two-pronged strategy they laid out in their F-1 earlier this year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.